After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi
pharmaphorum
JUNE 3, 2021
The approval and favourable label should position Lybalvi for great success, as people taking antipsychotic medication for schizophrenia or manic episodes in bipolar disorder often list weight gain as one of the most common and debilitating adverse reactions to treatment.
Let's personalize your content